Search company, investor...
Eikon Therapeutics company logo

Eikon Therapeutics

Founded Year



Series C | Alive

Total Raised


Last Raised

$106M | 3 days ago

About Eikon Therapeutics

Eikon Therapeutics operates as a biopharmaceutical company that specializes in drug discovery. The company's platform identifies compounds-protein interactions by measuring the effects of chemical compounds on the behavior of individual proteins in a live cellular environment. The company was founded in 2109 and is based in Hayward, California.

Headquarters Location

3929 Point Eden Way

Hayward, California, 94545,

United States


Missing: Eikon Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eikon Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eikon Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eikon Therapeutics is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,215 items

Eikon Therapeutics Patents

Eikon Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell imaging
  • Fluorescent dyes
patents chart

Application Date

Grant Date


Related Topics




Application Date


Grant Date


Related Topics



Latest Eikon Therapeutics News

Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline

Jun 1, 2023

HAYWARD, Calif.--(BUSINESS WIRE)-- #Biotech--Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. Eikon successfully completed three transactions, including the acquisition of global rights

Eikon Therapeutics Frequently Asked Questions (FAQ)

  • When was Eikon Therapeutics founded?

    Eikon Therapeutics was founded in 2019.

  • Where is Eikon Therapeutics's headquarters?

    Eikon Therapeutics's headquarters is located at 3929 Point Eden Way, Hayward.

  • What is Eikon Therapeutics's latest funding round?

    Eikon Therapeutics's latest funding round is Series C.

  • How much did Eikon Therapeutics raise?

    Eikon Therapeutics raised a total of $665.8M.

  • Who are the investors of Eikon Therapeutics?

    Investors of Eikon Therapeutics include The Column Group, Foresite Capital, Lux Capital, Innovation Endeavors, General Catalyst and 15 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.